Sanifit therapeutics
Webb22 juni 2024 · Razón Social SANIFIT THERAPEUTICS SA CIF A57306052 Capital Social 1133558.19 Euros Actividad Otra investigación y desarrollo experimental en ciencias naturales y técnicas Teléfono 97 143 99 25 Nombres Anteriores LABORATORIS SANIFIT SL Órgano Administración Consejo de administración Presidente Sigalas Alexandros Webb22 nov. 2024 · Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments …
Sanifit therapeutics
Did you know?
Webb4 nov. 2024 · Introduction: Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving maintenance hemodialysis. Webb22 nov. 2024 · Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase 3, developed for the treatment of calcific uremic …
Webb26 nov. 2024 · Shareholders of Sanifit will receive an upfront payment of EUR 205 million, clinical, regulatory and market access milestones for up to EUR 170 million and tiered … Webb18 juni 2024 · J.P. and B.I. are founders, employees and stockholders of Sanifit Therapeutics and co-inventors of patents owned or controlled by Sanifit Therapeutics. M.D.F. has received research grants and travel support from Sanifit Therapeutics, is a stockholder of Sanifit Therapeutics and is a co-inventor of a patent owned or controlled …
WebbFounders Joan Perelló. Operating Status Active. Last Funding Type Series D. Legal Name SANIFIT THERAPEUTICS, S.A. Company Type For Profit. Contact Email … Webb3 juni 2016 · Sanifit Therapeutics S. A. ClinicalTrials.gov Identifier: NCT02790073 Other Study ID Numbers: SNFCT2015_04 : First Posted: June 3, 2016 Key Record Dates: Results First Posted: August 28, 2024: Last Update Posted: August 28, 2024 Last Verified: August 2024 Keywords ...
Webb22 nov. 2024 · Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft …
WebbSanifit Therapeutics Oct 2024 - Nov 20243 years 2 months Greater San Diego Area Senior Vice President, Clinical Operations Mirati … teacher wants a rectangleWebb11 nov. 2024 · SQN Clinical performed the statistical analyses with funding from Sanifit Therapeutics. Clinipace, a contract research organization, assisted with study management, site monitoring, and data collection. Editorial assistance for manuscript preparation was provided by Jonathan Latham of PharmaScribe, LLC and was funded by … teacher wanting to change careersWebb1 dec. 2024 · CSL Vifor, a world leading Nephrology, Iron Deficiency and Cardio-Renal pharmaceutical company, is experiencing rapid growth due to the realization, continued expansion, and optimization of its pipeline and portfolio strategy.We are currently looking for a Medical Affairs Officer (Quality Assurance, Regulatory Affairs, Pharmacovigilance) … south indian bank share valueWebb22 nov. 2024 · Sanifit Therapeutics and Inositec AG, both clinical stage biopharmaceutical companies, are developing first-in-class treatments for progressive vascular calcification and soft tissue disorders. Sanifit’s SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase-III, developed for the treatment of calcific uremic ... south indian bank sharjahWebbOn 17 July 2012, orphan designation (EU/3/12/1026) was granted by the European Commission to Sanifit Laboratoris, S.L., Spain, for hexasodium phytate for the treatment of calciphylaxis. In October 2015, Sanifit Laboratoris, S.L. changed name to Laboratoris Sanifit S.L. In April 2024, Laboratoris Sanifit S.L. changed name to Sanifit Therapeutics ... south indian bank short formWebb28 apr. 2024 · About Cara Therapeutics Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated … south indian bank siliguriWebbThe Netherlands. Spanish Therapeutics company developing treatment of vascular calcification disorders of kidney patients. Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. Sanifit’s lead compound, SNF472, is a promising drug for the treatment of calciphylaxis or CUA ... teacher wardrobe 2020